Gumbiner B - Search Results

1

Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.

Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW. Buse JB, et al. Among authors: gumbiner b. Diabetes Care. 1998 Sep;21(9):1455-61. doi: 10.2337/diacare.21.9.1455. Diabetes Care. 1998. PMID: 9727891 Clinical Trial.

2

Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial.

Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Henry RR, et al. Among authors: gumbiner b. Diabetes Care. 1993 Jan;16(1):21-31. doi: 10.2337/diacare.16.1.21. Diabetes Care. 1993. PMID: 8422777 Clinical Trial.

3

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.

Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Suter SL, et al. Among authors: gumbiner b. Diabetes Care. 1992 Feb;15(2):193-203. doi: 10.2337/diacare.15.2.193. Diabetes Care. 1992. PMID: 1547676

4

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI. Maggs DG, et al. Among authors: gumbiner b. Ann Intern Med. 1998 Feb 1;128(3):176-85. doi: 10.7326/0003-4819-128-3-199802010-00002. Ann Intern Med. 1998. PMID: 9454525 Clinical Trial.

5

Effects of aging on insulin secretion.

Gumbiner B, Polonsky KS, Beltz WF, Wallace P, Brechtel G, Fink RI. Gumbiner B, et al. Diabetes. 1989 Dec;38(12):1549-56. doi: 10.2337/diab.38.12.1549. Diabetes. 1989. PMID: 2684711

6

Effects of a monounsaturated fatty acid-enriched hypocaloric diet on cardiovascular risk factors in obese patients with type 2 diabetes.

Gumbiner B, Low CC, Reaven PD. Gumbiner B, et al. Diabetes Care. 1998 Jan;21(1):9-15. doi: 10.2337/diacare.21.1.9. Diabetes Care. 1998. PMID: 9538963 Clinical Trial.

7

Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM.

Polonsky KS, Gumbiner B, Ostrega D, Griver K, Tager H, Henry RR. Polonsky KS, et al. Among authors: gumbiner b. Diabetes. 1994 Jul;43(7):871-7. doi: 10.2337/diab.43.7.871. Diabetes. 1994. PMID: 8013750

8

Potentiation of effects of weight loss by monounsaturated fatty acids in obese NIDDM patients.

Low CC, Grossman EB, Gumbiner B. Low CC, et al. Among authors: gumbiner b. Diabetes. 1996 May;45(5):569-75. doi: 10.2337/diab.45.5.569. Diabetes. 1996. PMID: 8621005 Clinical Trial.

9

Treating obesity in type 2 diabetes. Calories, composition, and control.

Gumbiner B. Gumbiner B. Diabetes Care. 1999 Jun;22(6):886-8. doi: 10.2337/diacare.22.6.886. Diabetes Care. 1999. PMID: 10372236 Review. No abstract available.

10

Benefits and limitations of very-low-calorie diet therapy in obese NIDDM.

Henry RR, Gumbiner B. Henry RR, et al. Among authors: gumbiner b. Diabetes Care. 1991 Sep;14(9):802-23. doi: 10.2337/diacare.14.9.802. Diabetes Care. 1991. PMID: 1959474 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

174 results

Search Page